SAM
TGTX icon

Senzar Asset Management’s TG Therapeutics TGTX Stock Holding History

Senzar Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-31,594
Closed -$415K – 15
2018
Q2 		$415K Sell
31,594
-444,324
-93% -$6.11M 1.2% 20
2018
Q1 		$6.76M Sell
475,918
-879,260
-65% -$11.2M 2.13% 18
2017
Q4 		$11.1M Buy
1,355,178
+491,678
+57% +$4.3M 2.84% 13
2017
Q3 		$10.2M Sell
863,500
-105,800
-11% -$1.21M 2.5% 11
2017
Q2 		$9.74M Sell
969,300
-170,600
-15% -$1.91M 2.4% 14
2017
Q1 		$13.3M Buy
+1,139,900
New +$8.18M 3.36% 9

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM

Senzar Asset Management's TGTX Position: Q3 2018 in Review

Senzar Asset Management sold out of TG Therapeutics (TGTX) in Q3 2018, closing a stake of 31,594 shares — an estimated $415K sold.

Senzar Asset Management first reported a position in TGTX in Q1 2017 and held it in 6 quarters. The position peaked at $13.3M in Q1 2017. 127 funds tracked by Wall St. Rank hold TGTX as of Q3 2018.

  • Senzar Asset Management reported no remaining TG Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Senzar Asset Management sold 31,594 TG Therapeutics shares in Q3 2018, an estimated $415K.
  • Senzar Asset Management first reported a position in TG Therapeutics in Q1 2017 and held it in 6 quarters.
  • Senzar Asset Management's TG Therapeutics position peaked at $13.3M in Q1 2017.
  • 127 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2018.

Based on Senzar Asset Management's 13F filing for Q3 2018.